A randomized, double-blind, placebo-controlled phase I.a clinical study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple subcutaneous dose escalation of MWN109 injection in Chinese healthy volunteers
Latest Information Update: 12 Sep 2025
At a glance
- Drugs MWN 109 (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 12 Sep 2025 New trial record